SCHEMBL5210663

SCHEMBL5210663

CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)NC(=O)CC3)ncc1C(F)(F)F)S(C)(=O)=O

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 20/20 0.89
PTK2B Q14289 5/20 0.89
PLK4 O00444 1/20 0.81
AURKA O14965 1/20 0.81
PDPK1 O15530 1/20 0.81
DAPK3 O43293 1/20 0.81
JAK2 O60674 1/20 0.81
ROCK2 O75116 1/20 0.81
STK16 O75716 1/20 0.81
PRKD3 O94806 1/20 0.81
MAP4K4 O95819 1/20 0.81
PAK4 O96013 1/20 0.81
CHEK2 O96017 1/20 0.81
NTRK1 P04629 1/20 0.81
PRKCG P05129 1/20 0.81
INSR P06213 1/20 0.81
LCK P06239 1/20 0.81
FYN P06241 1/20 0.81
CDK1 P06493 1/20 0.81
LYN P07948 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217154 0.94 PTK2 (1.00) PTK2PTK2BPLK4AURKAPDPK1
SCHEMBL5185817 0.94 PTK2 (0.89) PTK2PTK2BPLK4AURKAPDPK1
SCHEMBL5209509 0.90 PTK2 (0.80) PTK2PTK2BPLK4AURKAPDPK1
Pf-00562271 SCHEMBL1206959 0.89 PTK2 (1.00) PTK2PTK2BPLK4AURKAPDPK1
Pf-00562271 SCHEMBL29637167 0.89 PTK2 (1.00) PTK2PTK2BPLK4AURKAPDPK1
Pf-00562271 SCHEMBL29381854 0.89 PTK2 (1.00) PTK2PTK2BPLK4AURKAPDPK1
Pf-00562271 SCHEMBL29496512 0.89 PTK2 (0.99) PTK2PTK2BPLK4AURKAPDPK1
Pf-00562271 SCHEMBL21062022 0.89 PTK2 (0.99) PTK2PTK2BPLK4AURKAPDPK1
SCHEMBL13056408 0.86 PTK2 (0.80) PTK2PTK2BPLK4AURKAPDPK1
SCHEMBL19203861 0.86 PTK2 (0.83) PTK2PTK2BPLK4AURKAPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235562-B2 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2007-06-26 US claimed
EP-1758887-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Incorporated (US) 2007-03-07 EP claimed
WO-2005111016-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2005-11-24 WO claimed
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC 2005-11-17 US claimed
US-7235562-B2 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2007-06-26 US disclosed
EP-1758887-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Incorporated (US) 2007-03-07 EP disclosed
WO-2005111016-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2005-11-24 WO disclosed
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth TYMS, TYMP, CCNA1 PTK2 3610/4885PTK2B 3168/4885PLK4 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.